May 21, 2021 - Evolution of FMT

Evolution of FMT – From Early Clinical to Standardized Treatments
A Virtual Meeting
15:00 - 18:00 CEST // 9:00am - 12:00pm EDT



Meeting objectives

Faecal microbiota transplantation (FMT) is widely reported to be an effective treatment against recurrent Clostridium difficile infections. Recent clinical evidences support the therapeutic use of FMT for several other pathologies including inflammatory bowel disease, cancer and other functional or metabolic disorders.

Initial guidelines are now available to overcome some of the technical and logistical issues in establishing a non-standardised treatment into clinical practice with proper safety and governance.


Along with recent clinical successes of FMT, the webinar aims to provide a multi-disciplinary perspective of ongoing efforts to develop FMT guidelines including technical, regulatory, and standardization requirements.

Recognized experts will give insights into state-of-the art approaches and standards developed by international organizations and institutions.



Dr. Hervé Affagard, MaaT Pharma

Dr. Chrysi Sergaki, NIBSC
Biosketch Abstract

Prof. Harry Sokol, St. Antoine Hospital, Paris
Biosketch Abstract

Dr. Vincent Thomas, Bioaster
Biosketch Abstract

Dr. Jennifer Wargo, MD Anderson Cancer Center

Dr. Gary Wu, University of Pennsylvania


Scientific Committee
Phil Daschner, NIH
Cyril Guyard, Bioaster
Shawn Novick, IABS
Philippe Sabot, IABS
Stephanie Servetas, NIST
Vincent Thomas, Bioaster

With our Thanks to our Sponsors,


View the webinar:


International Alliance for Biological Standardization

Twitter Feed

We wish all of our partners and friends a Great year 2022 !
Few more days to register to the IABS 7th Stats meeting: Accelerating Drug Development: How QbD, Regulatory Partner…
Follow IABS-Int. Alliance for Biological Standardization on Twitter

Contact Info

IABS, Rue Mina-Audemars, 3
CH-1204 Geneva

+ 41 22 301 10 36
This email address is being protected from spambots. You need JavaScript enabled to view it.